Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Deuterated Tryptamine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I/ Phase II
Sponsor : Cybin
Deal Size : Undisclosed
Deal Type : Partnership
Details : Under the partnership, Worldwide Clinical Trials will support clinical developments of CYB003, an investigational proprietary deuterated analog of psilocybin, currently in Phase 2 trial for the treatment of major depressive disorder.
Product Name : CYB003
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 26, 2023
Lead Product(s) : Deuterated Tryptamine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I/ Phase II
Sponsor : Cybin
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Bryostatin-1
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Neurotrope
Deal Size : Undisclosed
Deal Type : Agreement
Details : Neurotrope has entered into a services agreement with Worldwide Clinical Trials to support site recruitment and activation for the Company's ongoing Phase 2 study of bryostatin-1 in the treatment of moderately severe Alzheimer's disease.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 30, 2020
Lead Product(s) : Bryostatin-1
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Neurotrope
Deal Size : Undisclosed
Deal Type : Agreement